Home › NDC Lookup › RxCUI directory › RxCUI 2557906

Glecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet — RxCUI 2557906

RxNorm drug concept · Semantic clinical drug
RxCUI 2557906 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2557906
Official nameGlecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asglecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet
FDA products mapped2
Package NDCs mapped5
Reported Medicaid activity (SDUD)44,772 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Glecaprevir and Pibrentasvir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • For most patients who have never been treated before, Mavyret is taken for just 8 weeks — which is shorter than many older hepatitis C treatments. If you've been treated before or...
  • How long do I have to take Mavyret, and will it actually cure my hepatitis C?
  • Yes, and this one really matters. Food — even a moderate-fat meal — significantly increases how much of both medicines gets absorbed into your bloodstream. Taking Mavyret on an emp...
  • Do I really need to take it with food every single day?
📖 Read our full Glecaprevir and Pibrentasvir guide →

🕸️ Concept Web — How Glecaprevir 50 MG / pibrentasvir 20 MG Oral Pell... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Glecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet RxCUI 2557906

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Glecaprevir 1940635
    • Pibrentasvir 1940636
    • Glecaprevir / pibrentasvir 1940702
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mavyret 1940704
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Glecaprevir / pibrentasvir Oral Pellet 2557905
    • Glecaprevir / pibrentasvir Oral Product 1940699
    • Glecaprevir / pibrentasvir Pellet Product 2557904
    • Glecaprevir / pibrentasvir Oral Pellet [Mavyret] 2557908
    • Mavyret Oral Product 1940707
    • Mavyret Pellet Product 2557909
    • Oral Pellet 317691
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Glecaprevir 50 MG SCDC · 2557902
  • Pibrentasvir 20 MG SCDC · 2557903
  • Glecaprevir / pibrentasvir Oral Pellet SCDF · 2557905
  • Glecaprevir / pibrentasvir Oral Product SCDG · 1940699
  • Glecaprevir / pibrentasvir Pellet Product SCDG · 2557904

Brand-Name Concepts

  • Glecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet [Mavyret] SBD · 2557910
  • Glecaprevir 50 MG / pibrentasvir 20 MG [Mavyret] SBDC · 2557907
  • Glecaprevir / pibrentasvir Oral Pellet [Mavyret] SBDF · 2557908
  • Mavyret Oral Product SBDG · 1940707
  • Mavyret Pellet Product SBDG · 2557909
  • Mavyret BN · 1940704

📦 FDA Products & Package NDCs

2 products · 5 package NDCs
5 package NDCs map to RxCUI 2557906 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-2600-28 1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET Mavyret AbbVie Inc. 2021-06-22
00074-2625-04 4 CARTON in 1 CARTON (0074-2625-04) / 7 BLISTER PACK in 1 C... Mavyret AbbVie Inc. 2025-04-15
00074-2625-28 4 CARTON in 1 CARTON (0074-2625-28) / 7 DOSE PACK in 1 CART... Mavyret AbbVie Inc. 2017-08-03
00074-2625-56 2 CARTON in 1 CARTON (0074-2625-56) / 4 CARTON in 1 CARTON... Mavyret AbbVie Inc. 2017-08-03
00074-2625-84 84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84) Mavyret AbbVie Inc. 2021-06-22
Observed labelers: AbbVie Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.